<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:hpo ids='HP_0005505'>Refractory anemia</z:hpo> (RA) is a very <z:hpo ids='HP_0001425'>heterogeneous</z:hpo> disease regarding biological and clinical features </plain></SENT>
<SENT sid="1" pm="."><plain>The International Prognostic Scoring System (IPSS) was useful for assessing the prognosis in the whole group of 219 <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) patients </plain></SENT>
<SENT sid="2" pm="."><plain>However, the IPSS was not sufficient in 132 RA patients </plain></SENT>
<SENT sid="3" pm="."><plain>To predict survival and freedom from <z:hpo ids='HP_0004808'>acute myeloid leukemia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>) evolution, we investigated individual prognostic factors based on the clinical parameters (age, gender, morphologic features, cytopenias and cytogenetics) of 132 RA patients using univariate and multivariate analyses </plain></SENT>
<SENT sid="4" pm="."><plain>Based on the results, we devised a new system for assessing the prognosis of RA patients </plain></SENT>
<SENT sid="5" pm="."><plain>In our system, RA patients with pseudo-<z:e sem="disease" ids="C0030779" disease_type="Disease or Syndrome" abbrv="">Pelger-Huët anomalies</z:e> &gt;/=3% were classified as high risk (12 patients); of patients without pseudo-<z:e sem="disease" ids="C0030779" disease_type="Disease or Syndrome" abbrv="">Pelger-Huët anomalies</z:e> &gt;/=3%, those with intermediate/poor karyotype according to IPSS, Hb &lt;/=6 g/dl or mMgk &gt;/=10% were classified as intermediate risk (57 patients); and those without high or intermediate risk were classified as low risk (67 patients) </plain></SENT>
<SENT sid="6" pm="."><plain>In our system, the analyses of both survival times and <z:hpo ids='HP_0001909'>leukemia</z:hpo>-free survival times revealed significant differences among the three groups (P &lt; 0.0001) </plain></SENT>
</text></document>